4 High-Use Drugs That Will Have Lower Medicare Prices – And 3 Others Facing Negotiations – Image for illustrative purposes only (Image credits: Unsplash)
Millions of older Americans are beginning to see meaningful reductions in their monthly prescription costs as the first round of Medicare drug price negotiations takes full effect in 2026. The changes target some of the most commonly prescribed medications for conditions that affect large numbers of retirees, including blood clots, diabetes, and heart disease. For many seniors living on fixed incomes, these adjustments represent the first sustained relief from prices that have long strained household budgets.
Why the Changes Matter for Retirees
Prescription drug spending has grown steadily for Medicare beneficiaries, often outpacing other retirement expenses such as housing and groceries. The negotiation program allows Medicare to set maximum fair prices for selected high-use drugs, replacing the previous system in which manufacturers set list prices with little direct oversight. The initial round covers medications that together serve millions of Part D enrollees each year.
Early data show price reductions ranging from roughly 50 percent to more than 75 percent on several products. These savings flow through Medicare Advantage and stand-alone Part D plans, lowering both plan premiums and the amounts beneficiaries pay at the pharmacy counter. The program is structured to expand over time, with additional drugs entering negotiations in subsequent years.
Price Reductions on Blood Thinners and Diabetes Treatments
Two widely prescribed blood thinners and two diabetes medications anchor the first set of negotiated prices. Eliquis, used to reduce stroke risk in patients with atrial fibrillation, moved from a previous monthly list price above $500 to a negotiated amount near $231. Xarelto, another common anticoagulant, dropped from roughly $517 to about $197 for a 30-day supply.
On the diabetes side, Jardiance fell from approximately $573 to $197 monthly, while Januvia saw one of the steepest cuts, declining from about $527 to $113. These four medications address chronic conditions that require consistent, long-term use. Lower costs can improve adherence and reduce the need for seniors to ration doses or seek assistance programs.
| Medication | Previous Monthly Price | Negotiated Monthly Price |
|---|---|---|
| Eliquis | Over $500 | $231 |
| Jardiance | $573 | $197 |
| Januvia | $527 | $113 |
| Xarelto | $517 | $197 |
Specialty Drugs Also See Adjustments
The negotiation process extends beyond maintenance medications to include several high-cost specialty products. Imbruvica, used for certain blood cancers, previously carried monthly prices near $15,000 before receiving a substantial reduction. Stelara and Enbrel, prescribed for autoimmune conditions such as psoriasis, rheumatoid arthritis, and Crohn’s disease, likewise received negotiated discounts.
Even after the cuts, these therapies remain expensive. The lower prices nevertheless ease the financial pressure that often forces patients to delay treatment or exhaust savings accounts. Medicare officials expect the changes to improve access for beneficiaries who previously faced coverage gaps or high copays.
Next Round Targets Additional High-Profile Medications
A second negotiation cycle is already underway and includes several medications that have drawn widespread attention in recent years. Ozempic and Wegovy, both GLP-1 receptor agonists used for diabetes and weight management, are among the drugs selected. Trelegy Ellipta, a treatment for chronic obstructive pulmonary disease, also enters the process.
Negotiated prices for this group are scheduled to take effect in 2027. The inclusion of these products reflects Medicare’s focus on areas of rapid spending growth. Seniors who rely on these therapies may see further cost relief once the new prices are implemented.
What matters now: The first wave of negotiated prices is already lowering out-of-pocket costs for many Medicare beneficiaries. Additional savings are expected as the program continues and more drugs reach negotiated status in coming years.
The shift in how Medicare sets drug prices marks a lasting change in the economics of retirement healthcare. Seniors who take multiple prescriptions stand to save the most, while the broader program continues to evolve with each new negotiation round. Over time, the cumulative effect could ease a significant portion of the prescription burden that has long weighed on older households.
